2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2462 Regimen-specific immune trajectories define gvhd risk after haploidentical transplantation

Zengkai Pan, Xiaowei Xie, PhD2, Ting Lu3, Jingtao Huang, PhD4, Huihong Huang5, Yang He6, Chuanhe Jiang7, Luxiang Wang8, Jiayu Huang, MD9, Zilu Zhang, MD10, Haiyang LU11, Tao Cheng12, Jiahao Chen13, Hui Cheng, PhD14, Jun Wei15, Xiaoxia Hu, MD16
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

INTRODUCTION

Haploidentical hematopoietic cell transplantation (Haplo-HCT) has become an increasingly accessible curative therapy for patients with hematologic malignancies. Antithymocyte globulin (ATG) and posttransplant cyclophosphamide (PTCy) are widely used graft-versus-host disease (GvHD) prophylaxis strategies. Although both approaches effectively reduce acute GvHD (aGvHD), whether they generate distinct immune-reconstitution trajectories that shape subsequent GvHD and transplant outcomes remains poorly defined.

RATIONALE

GvHD prophylaxis strategies represent distinct immune interventions that may impose different selective pressures on donor and recipient immune compartments during immune recovery. We hypothesized that ATG- and PTCy-based prophylaxis establish regimen-specific temporal immune trajectories that precede clinical GvHD and identify patients at risk for adverse outcomes.

RESULTS

We analyzed clinical outcomes in 457 recipients undergoing haplo-HSCT with ATG- or PTCy-based prophylaxis and integrated longitudinal immune profiling, including early mass cytometry, plasma cytokine analysis, single-cell RNA sequencing with paired T cell receptor sequencing, longitudinal CyTOF profiling, and flow cytometric validation.

ATG and PTCy achieved comparable control of grade II–IV aGvHD but were associated with distinct downstream clinical trajectories. Among patients developing aGvHD, both ATG- and PTCy-associated grade II–IV aGvHD were linked to increased non-relapse mortality, whereas PTCy was associated with a greater burden of moderate-to-severe chronic GvHD (cGvHD). Early immune profiling before clinical aGvHD identified prophylaxis-specific immune states, including an ATG-associated inflammatory T cell program enriched for Th17 features and a distinct PTCy-associated CD4 T cell remodeling state. Longitudinal immune profiling revealed divergent recovery patterns across T cell, NK cell, B cell, and myeloid compartments. Regimen-specific day 30 immune states further stratified late GvHD risk: impaired NK cell recovery was associated with adverse outcomes after ATG-based prophylaxis, whereas altered CD8 T cell remodeling was associated with subsequent moderate-to-severe cGvHD after PTCy-based prophylaxis. These immune-risk associations were independently supported by conventional flow cytometry.

CONCLUSION

ATG and PTCy should not be viewed simply as alternative GvHD prophylaxis regimens with equivalent clinical effects; rather, they establish distinct temporal immune trajectories associated with different patterns of acute and chronic GvHD. These findings provide a framework for regimen-adapted immune monitoring and personalized risk stratification after haplo-HCT.

Zengkai Pan: No relevant conflicts of interest to declare.